Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD-dominant medicinal cannabis and THC detectability in cancer patients
ACTRN12622000974707Phase 4Completed
- Sponsor
- Mater Misericordiae University Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of LGP Classic CBD in cancer (3 arms), sponsored by Mater Misericordiae University Hospital. Primary endpoints: Detection of THC in urine, Detection of THC in saliva and 1 more. Started Mar 2023; status: completed.
02
Drugs
LGP Classic CBD
03
Conditions
cancer
Beyond the preview
Go deeper on ACTRN12622000974707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000974707.